<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:5pt Arial, sans-serif; }
 .font1 { font:7pt Arial, sans-serif; }
 .font2 { font:9pt Arial, sans-serif; }
 .font3 { font:10pt Arial, sans-serif; }
 .font4 { font:14pt Arial, sans-serif; }
 .font5 { font:18pt Arial, sans-serif; }
 .font6 { font:20pt Arial, sans-serif; }

</style>
</head>
<body>
<p><span class="font4">Deutsche Bank</span></p>
<p><span class="font4">Markets Research</span></p>
<div>
<p><span class="font3">Rating</span></p><a name="caption1"></a>
<h1><a name="bookmark0"></a><span class="font6"><a name="bookmark1"></a>Buy</span></h1>
<p><span class="font2">Asia</span></p>
<p><span class="font2">China</span></p>
<p><span class="font2">Health Care</span></p>
<p><span class="font2">Pharmaceuticals /</span></p>
<p><span class="font2">Biotechnology</span></p>
</div><br clear="all">
<div>
<p><span class="font3">Company</span></p>
<h1><a name="bookmark2"></a><span class="font6"><a name="bookmark3"></a>China Biologie Products</span></h1>
</div><br clear="all">
<div>
<p><span class="font1">Reuters &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bloomberg &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exchange Ticker</span></p>
<p><span class="font1">CBPO.OQ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CBPOUS &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NMS &nbsp;&nbsp;&nbsp;CBPO</span></p>
</div><br clear="all">
<div>
<h2><a name="bookmark4"></a><span class="font5"><a name="bookmark5"></a>Overdelivered with a bang</span></h2>
</div><br clear="all">
<div>
<p><span class="font2">Solid 2Q; guidance maintained</span></p>
<p><span class="font2">CBPO reported revenue/non-GAAP EPS of USD79m/1.06 in 2015, vs. consensus of 72m/0.85 and our estimate of 72m/0.92. These represent YoY growth of 32%/30% respectively. Robust growth was driven by above-industry production volume growth, robust growth for flagship products as well as better-than-expected operating leverage. We highlight that both albumin and IVIG experienced 2.2%/2.3% ex-FX ASP growth in 2015 due to VAT reduction and improved penetration. The company maintained guidance for 2015.</span></p>
<p><span class="font2">Robust growth achieved for both albumin and IVIG</span></p>
<p><span class="font2">We highlight growth for albumin and IVIG was 37.6%/28.8% in 2015 vs. 13.1W60.1% in 1015 and 6.6%/27.2% in 2014. For albumin, the strong growth was due to the delayed batch approval from 1015 and a low base in 2014 as the Guizhou facility was suspended. For IVIG, growth drivers included increased coverage in tier one cities and new markets, and production resumption of Guizhou facility. We highlight that ex-FX ASP growth of albumin and IVIG was 2.2%/2.3% in 2015, continuing the ASP improvement trend. We believe the Guizhou facility had a temporary disruption in May/June, which may lead to lower growth in 3015; however, growth is likely to accelerate again in 4015 as products derived from the acquired plasma will be sold.</span></p>
<p><span class="font2">0PM rose to a new high but not likely to be sustained in 2H15</span></p>
<p><span class="font2">GM and 0PM was 65.8%/50.9% in 2015 vs. 68.5%/48.1% in 1015. The company attributed GM erosion to the increase in plasma costs, which is inline with the industry average. We expect GM to be stable in 3015 but further erode in 4015 as product sales from acquired plasma will start. 0PM reached a new high of 50.9% due to 1) lower selling expenses for placenta polypeptide as the company stopped using third-party sales for the product in May 2014; 2) lower R&amp;D expenses as the company received a government subsidy of USD0.9m. However, the company indicated that 0PM might not sustain at the current level for 2H15.</span></p>
</div><br clear="all">
<div>
<p><span class="font2">Maintaining target price of USD149; risks</span></p>
<p><span class="font2">Our target price of USD149 is based on 33x 2016E EPS of USD3.60. We believe the 33x is justified as its global peers are trading at 25x with 1% EPS growth in 2016 (vs. 25% we model for CBPO). We believe a premium is justified as it is a scarcity play with strong earnings growth. Key risks include disruption of plasma collection, costs inflation, and delays in product launch.</span></p>
</div><br clear="all">
<div>
<p><span class="font1">Forecasts And Ratios</span></p>
<table border="1">
<tr><td style="vertical-align:top;">
<p><span class="font1">Year End Dec31</span></p></td><td style="vertical-align:top;">
<p><span class="font1">2013A</span></p></td><td style="vertical-align:top;">
<p><span class="font1">2014A</span></p></td><td style="vertical-align:top;">
<p><span class="font1">2015E</span></p></td><td style="vertical-align:top;">
<p><span class="font1">2016E</span></p></td><td style="vertical-align:top;">
<p><span class="font1">2017E</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">Sales (USDm)__</span></p></td><td style="vertical-align:top;">
<p><span class="font1">203.4</span></p></td><td style="vertical-align:top;">
<p><span class="font1">243.3</span></p></td><td style="vertical-align:top;">
<p><span class="font1">295.6</span></p></td><td style="vertical-align:top;">
<p><span class="font1">357.0</span></p></td><td style="vertical-align:top;">
<p><span class="font1">426.9</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">DB EPS FD(USD)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">2.12</span></p></td><td style="vertical-align:top;">
<p><span class="font1">2.89</span></p></td><td style="vertical-align:top;">
<p><span class="font1">3.60</span></p></td><td style="vertical-align:top;">
<p><span class="font1">4.52</span></p></td><td style="vertical-align:top;">
<p><span class="font1">5.72</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">DB EPS growth (%)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">23.4</span></p></td><td style="vertical-align:top;">
<p><span class="font1">36.4</span></p></td><td style="vertical-align:top;">
<p><span class="font1">24.5</span></p></td><td style="vertical-align:top;">
<p><span class="font1">25.4</span></p></td><td style="vertical-align:top;">
<p><span class="font1">26.7</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">PER (x)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">11.9</span></p></td><td style="vertical-align:top;">
<p><span class="font1">15.9</span></p></td><td style="vertical-align:top;">
<p><span class="font1">34.3</span></p></td><td style="vertical-align:top;">
<p><span class="font1">27.3</span></p></td><td style="vertical-align:top;">
<p><span class="font1">21.6</span></p></td></tr>
</table>
<p><span class="font0" style="font-weight:bold;font-style:italic;text-decoration:underline;">Source: Deutsche Bank estimates, company data</span><span class="font0" style="font-weight:bold;font-style:italic;">____________________________________________________________________________________ </span><span class="font0" style="font-weight:bold;">' DB E PS is fully diluted end excludes non-recurring items</span></p>
<p><span class="font0" style="font-weight:bold;"><sup>2</sup> Multiples end yields calculations tee average historical prices for pest yearsandspot prices for current and future years, except P/B which uses the year end close</span></p>
</div><br clear="all">
<div>
<p><span class="font2">Date</span></p>
<p><span class="font2">7 August 2015</span></p>
<h3><a name="bookmark6"></a><span class="font4"><a name="bookmark7"></a>Results</span></h3>
</div><br clear="all">
<div>
</div><br clear="all">
<div>
<table border="1">
<tr><td style="vertical-align:top;">
<p><span class="font1">Price at 5 Aug 2015 (USD)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">123.43</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">Price target - 12mth (USD)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">149.00</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">52-week range (USD)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">123.83 -44.90</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">HANG SENG INDEX</span></p></td><td style="vertical-align:top;">
<p><span class="font1">24,514</span></p></td></tr>
</table>
<p><span class="font1">Jack Hu. Ph.D</span></p>
<p><span class="font1">Research Analyst (+852 ) 2203 6208</span></p>
<p><a href="mailto:jack.hu@db.com"><span class="font1">jack.hu@db.com</span></a></p>
<p><span class="font1">Line Yiu</span></p>
<p><span class="font1">Research Associate (+852) 2203 6248 </span><a href="mailto:linc.yiu@db.com"><span class="font1">linc.yiu@db.com</span></a></p>
</div><br clear="all">
<div>
</div><br clear="all">
<div>
</div><br clear="all">
<div>
<p><span class="font2">Deutsche Bank AG/Hong Kong</span></p>
<p><span class="font2">Deutsche Bank does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. DISCLOSURES AND ANALYST CERTIFICATIONS ARE LOCATED IN APPENDIX 1. MCI (P) 124/04/2015.</span></p>
</div><br clear="all">
</body>
</html>